Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled trial of tralokinumab in asthma
2013-005615-27Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tralokinumab with Placebo (2 arms). Primary endpoint: Annual asthma exacerbation rate. Started Aug 2014; status: completed.
02
Drugs
tralokinumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2013-005615-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005615-27.